Objective:To analyze the application effect of recombinant human brain natriuretic peptide(rhBNP)as adjuvant therapy in elderly patients with decompensated heart failure(DHF).Methods:A total of 96 elderly patients with DHF were randomly divided into a control group and an observation group,with 48 patients in each group.Patients in the control group were treated with levosimendan,while those in the observa-tion group received adjuvant therapy with rhBNP.Clinical treatment outcomes,changes in serum markers(copeptin,N-terminal pro-B-type natriuretic peptide(NT-proBNP),and endothelin-1(ET-1)),cardiac function(left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF),and cardiac output),and adverse reactions were ob-served in both groups.Results:The total effective rate of clinical treatment in the observation group(91.67％)was higher than that in the control group(75.00％)(P＜0.05).After treatment,the levels of serum copep-tin,NT-proBNP,and ET-1 were lower in both groups compared to before treatment,and the levels in the observation group were lower than those in the control group(P＜0.05).The LVEDD and LVESD levels were lower in both groups after treatment compared to before,and the levels in the observation group were lower than those in the control group(P＜0.05).The LVEF and cardiac output levels were higher in both groups after treatment compared to before,and the levels in the observation group were higher than those in the control group(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions be-tween the two groups(P＞0.05).Conclusion:Adjuvant therapy with rhBNP in elderly patients with DHF can improve clinical efficacy,cardiac function,and prognosis,without significantly increasing adverse reactions.
关键词
重组人脑利钠肽/老年失代偿性心力衰竭/血清和肽素/心功能
Key words
Recombinant human brain natriuretic peptide/Elderly decompensated heart failure/Serum copeptin/Cardiac function
维普
万方数据